Does Lurbinectedin Interact with Other Medications?
Yes, lurbinectedin (brand name Zepzelca) interacts with several medications, primarily through CYP3A enzyme inhibition and other metabolic pathways. It moderately inhibits CYP3A in vitro, which can increase exposure to CYP3A substrates. Strong CYP3A inhibitors like ketoconazole raise lurbinectedin levels by 2.7-fold, while inducers like rifampin lower them by 52%.[1][2]
Key Drug Interactions to Watch For
- CYP3A Inhibitors (e.g., itraconazole, clarithromycin, grapefruit juice): Increase lurbinectedin exposure, raising toxicity risk. Avoid strong inhibitors during treatment and for 72 hours after; use caution with moderate ones.[1]
- CYP3A Inducers (e.g., rifampin, carbamazepine, St. John's wort): Decrease lurbinectedin effectiveness. Avoid during treatment and up to 5 half-lives before starting.[1]
- CYP2D6 Substrates (e.g., metoprolol, codeine): Lurbinectedin inhibits CYP2D6, potentially increasing levels of these drugs and causing adverse effects.[1]
- OATP1B1 Substrates (e.g., statins like atorvastatin): Risk of elevated substrate concentrations; monitor closely.[1]
No major interactions noted with PPIs, H2 blockers, or antacids, but spacing may be needed for oral drugs.[2]
How These Interactions Affect Treatment
Lurbinectedin is given IV every 21 days for small cell lung cancer, so interactions mainly impact co-medications. Dose adjustments aren't always required, but hold or reduce lurbinectedin if severe toxicity occurs with inhibitors. Therapeutic drug monitoring isn't standard, but pharmacists often recommend checking via tools like Lexicomp.[1][2]
Common Patient Scenarios and Risks
Patients on anticonvulsants (inducers) may see reduced efficacy, prompting therapy switches. Those with fungal infections on azoles face higher myelosuppression risk—neutropenia and fatigue are already common (57-79% incidence).[1][3] Elderly patients or those with liver impairment need extra caution, as interactions compound clearance issues.[2]
How to Manage Interactions
Consult a pharmacist or use interaction checkers before starting. No dedicated patents on lurbinectedin interactions limit generics yet, but core patents expire around 2031.[4] Report issues to FDA MedWatch.
Sources
[1]: Zepzelca Prescribing Information (FDA)
[2]: Drugs.com - Lurbinectedin Interactions
[3]: Clinical Pharmacology Review (FDA)
[4]: DrugPatentWatch.com - Lurbinectedin Patents